title: Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring.
abstract: The use of small-molecule kinase inhibitors has redefined the management of cancer. Chronic myelogenous leukaemia (CML) has become the paradigm for targeted cancer treatment. Imatinib has become the gold standard in the treatment of CML with excellent and durable responses and minimal side effects. Molecular diagnostics constitute an integral part of the routine monitoring. Results of cytogenetic analysis and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) indicate suboptimal response or treatment failure and guide treatment. New Abl kinase inhibitors such as nilotinib or dasatinib are options after the failure of or intolerance to imatinib, and both are available for first-line treatment of newly diagnosed CML. This review focuses on the prognostic significance of achieving a response at specific time points in patients with CML treated with imatinib, nilotinib or dasatinib in view of available data and current treatment recommendations.
authors.forename: Nikolas
authors.initials: N
authors.lastname: von Bubnoff
keywords: CML; matinib; myeloid neoplasms
references.citation: Nature. 1973 Jun 1;243(5405):290-3
references.pmid: 4126434
references.citation: Haematologica. 2010 Feb;95(2):224-31
references.pmid: 19833633
references.citation: Blood. 1994 Dec 15;84(12):4064-77
references.pmid: 7994025
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3659-63
references.pmid: 19487383
references.citation: Leukemia. 2003 Aug;17(8):1529-37
references.pmid: 12886239
references.citation: Blood. 1988 Jul;72(1):294-8
references.pmid: 3164637
references.citation: N Engl J Med. 1997 Jul 24;337(4):223-9
references.pmid: 9227927
references.citation: Blood. 1998 Sep 1;92(5):1541-8
references.pmid: 9716581
references.citation: Science. 1990 Mar 2;247(4946):1079-82
references.pmid: 2408149
references.citation: Br J Haematol. 1999 Dec;107(3):587-99
references.pmid: 10583264
references.citation: Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3395-400
references.pmid: 15705718
references.citation: Science. 2001 Aug 3;293(5531):876-80
references.pmid: 11423618
references.citation: Leukemia. 2009 Jun;23(6):1054-61
references.pmid: 19282833
references.citation: Leukemia. 2008 Jun;22(6):1200-6
references.pmid: 18401416
references.citation: Cancer. 2008 Feb 15;112(4):837-45
references.pmid: 18085610
references.citation: Clin Cancer Res. 1998 Jul;4(7):1661-72
references.pmid: 9676840
references.citation: Blood. 2005 Aug 1;106(3):1133-4; author reply 1134
references.pmid: 16033955
references.citation: N Engl J Med. 2006 Dec 7;355(23):2408-17
references.pmid: 17151364
references.citation: Science. 2004 Jul 16;305(5682):399-401
references.pmid: 15256671
references.citation: Blood. 2009 Sep 3;114(10):2168-71
references.pmid: 19589924
references.citation: Lancet. 2002 Feb 9;359(9305):487-91
references.pmid: 11853795
references.citation: N Engl J Med. 1986 Apr 24;314(17):1065-9
references.pmid: 3457264
references.citation: Cancer Cell. 2005 Feb;7(2):129-41
references.pmid: 15710326
references.citation: Leukemia. 2004 Apr;18(4):864-71
references.pmid: 14973502
references.citation: Blood. 2005 Sep 15;106(6):2128-37
references.pmid: 15914554
references.citation: Cancer Cell. 2002 Aug;2(2):117-25
references.pmid: 12204532
references.citation: N Engl J Med. 1999 Jul 15;341(3):164-72
references.pmid: 10403855
references.citation: Blood. 2002 May 1;99(9):3472-5
references.pmid: 11964322
references.citation: N Engl J Med. 2002 Feb 28;346(9):645-52
references.pmid: 11870241
references.citation: Blood. 2011 Feb 10;117(6):1822-7
references.pmid: 21030554
references.citation: Blood. 2006 Sep 1;108(5):1478-84
references.pmid: 16627756
references.citation: Leukemia. 2006 Nov;20(11):1925-30
references.pmid: 16990771
references.citation: J Clin Oncol. 2009 Dec 10;27(35):6041-51
references.pmid: 19884523
references.citation: Science. 1990 Feb 16;247(4944):824-30
references.pmid: 2406902
references.citation: J Natl Cancer Inst. 1998 Jun 3;90(11):850-8
references.pmid: 9625174
references.citation: Haematologica. 2003 Mar;88(3):260-7
references.pmid: 12651263
references.citation: Blood. 2008 Feb 15;111(4):1834-9
references.pmid: 18048643
references.citation: Haematologica. 2007 Apr;92(4):564-5
references.pmid: 17488671
references.citation: Clin Chem. 2004 Jul;50(7):1233-7
references.pmid: 15229152
references.citation: Blood. 2008 Aug 1;112(3):516-8
references.pmid: 18492956
references.citation: J Clin Oncol. 2008 Jul 10;26(20):3358-63
references.pmid: 18519952
references.citation: J Natl Cancer Inst. 1997 Nov 5;89(21):1616-20
references.pmid: 9362160
references.citation: Blood. 2002 Mar 15;99(6):1928-37
references.pmid: 11877262
references.citation: Leukemia. 2007 Mar;21(3):494-504
references.pmid: 17252012
references.citation: Pharmacoeconomics. 2007;25(6):481-96
references.pmid: 17523753
references.citation: Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2794-9
references.pmid: 16477019
references.citation: Blood. 2007 May 15;109(10):4143-50
references.pmid: 17264298
references.citation: Clin Cancer Res. 2002 Jul;8(7):2167-76
references.pmid: 12114417
references.citation: Blood. 2006 Oct 1;108(7):2332-8
references.pmid: 16772610
references.citation: Ther Drug Monit. 2005 Oct;27(5):634-40
references.pmid: 16175138
references.citation: Clin Cancer Res. 2007 Oct 15;13(20):6136-43
references.pmid: 17947479
references.citation: Leukemia. 2006 Apr;20(4):664-70
references.pmid: 16482210
references.citation: Leukemia. 2006 Aug;20(8):1400-7
references.pmid: 16728981
references.citation: Clin Cancer Res. 2006 May 15;12(10):3037-42
references.pmid: 16707599
references.citation: N Engl J Med. 2010 Dec 23;363(26):2511-21
references.pmid: 21175313
references.citation: Leuk Res. 2009 Feb;33(2):271-5
references.pmid: 18762338
references.citation: J Clin Oncol. 2009 Jul 20;27(21):3472-9
references.pmid: 19487385
references.citation: Cancer. 2007 Jun 15;109(12):2466-72
references.pmid: 17503437
references.citation: Cancer. 2009 Aug 15;115(16):3709-18
references.pmid: 19517462
references.citation: Blood. 2011 Jan 27;117(4):1141-5
references.pmid: 21098399
references.citation: Blood. 2008 Dec 1;112(12):4437-44
references.pmid: 18716134
references.citation: Blood. 2007 Apr 15;109(8):3496-9
references.pmid: 17192396
references.citation: Leukemia. 2006 Jun;20(6):1028-34
references.pmid: 16617318
references.citation: Leukemia. 2008 Dec;22(12):2176-83
references.pmid: 18754032
references.citation: J Clin Oncol. 2009 Jul 1;27(19):3141-7
references.pmid: 19451435
references.citation: Blood. 2006 Jul 15;108(2):697-704
references.pmid: 16597591
references.citation: Blood. 2007 Jun 1;109(11):5011-5
references.pmid: 17303698
references.citation: Blood. 2001 Nov 15;98(10):3074-81
references.pmid: 11698293
references.citation: J Clin Oncol. 2008 Jul 1;26(19):3204-12
references.pmid: 18541900
references.citation: Blood. 2007 Jun 15;109(12):5143-50
references.pmid: 17317857
references.citation: Lancet Oncol. 2010 Nov;11(11):1029-35
references.pmid: 20965785
references.citation: Haematologica. 2009 Sep;94(9):1227-35
references.pmid: 19608684
references.citation: Cancer. 2007 Oct 1;110(7):1509-19
references.pmid: 17702093
references.citation: Blood. 2002 Aug 1;100(3):1014-8
references.pmid: 12130516
references.citation: Haematologica. 2008 Dec;93(12):1792-6
references.pmid: 18838477
references.citation: Blood. 2009 May 7;113(19):4497-504
references.pmid: 19264678
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2761-7
references.pmid: 20421539
references.citation: J Natl Cancer Inst. 1999 Jan 20;91(2):163-8
references.pmid: 9923858
references.citation: Blood. 2008 Apr 15;111(8):4022-8
references.pmid: 18256322
references.citation: J Natl Compr Canc Netw. 2009 Oct;7(9):984-1023
references.pmid: 19878641
references.citation: N Engl J Med. 2001 Apr 5;344(14):1038-42
references.pmid: 11287973
references.citation: Clin Cancer Res. 2005 May 1;11(9):3425-32
references.pmid: 15867244
references.citation: Haematologica. 2009 Feb;94(2):205-12
references.pmid: 19144656
references.citation: N Engl J Med. 2003 Mar 13;348(11):994-1004
references.pmid: 12637609
references.citation: Cancer. 2005 May 15;103(10):2099-108
references.pmid: 15830345
references.citation: Haematologica. 2010 Aug;95(8):1415-9
references.pmid: 20305139
references.citation: Nat Med. 1996 May;2(5):561-6
references.pmid: 8616716
references.citation: Blood. 2002 May 15;99(10):3530-9
references.pmid: 11986204
references.citation: N Engl J Med. 2010 Jun 17;362(24):2251-9
references.pmid: 20525993
references.citation: Leukemia. 2006 Jun;20(6):1047-54
references.pmid: 16598311
references.citation: Blood. 2009 May 21;113(21):5058-63
references.pmid: 19282457
references.citation: Blood. 1984 Apr;63(4):789-99
references.pmid: 6584184
references.citation: Br J Haematol. 2000 Sep;110(3):573-6
references.pmid: 10997966
references.citation: Leukemia. 2007 Mar;21(3):489-93
references.pmid: 17252009
references.citation: Blood. 2010 Nov 11;116(19):3758-65
references.pmid: 20679528
references.citation: N Engl J Med. 2010 Jun 17;362(24):2260-70
references.pmid: 20525995
references.citation: Cancer Genet Cytogenet. 2010 Jun;199(2):76-80
references.pmid: 20471509
references.citation: Blood. 2006 Jul 1;108(1):28-37
references.pmid: 16522812
references.citation: Blood. 2003 May 15;101(10):3794-800
references.pmid: 12560227
references.citation: Blood. 2008 Oct 15;112(8):3348-54
references.pmid: 18669873
references.citation: Blood. 2007 Oct 15;110(8):2991-5
references.pmid: 17625066
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3881-8
references.pmid: 18559609
references.citation: Cancer Res. 2005 Jun 1;65(11):4500-5
references.pmid: 15930265
references.citation: Clin Chem. 2004 Jul;50(7):1205-13
references.pmid: 15107311
references.citation: Blood. 2006 Oct 15;108(8):2811-3
references.pmid: 16809614
references.citation: Blood. 2007 Nov 15;110(10):3540-6
references.pmid: 17715389
references.citation: N Engl J Med. 2003 Oct 9;349(15):1423-32
references.pmid: 14534335
references.citation: Blood. 2007 Dec 1;110(12):4064-72
references.pmid: 17761829
references.citation: Blood. 2004 Dec 1;104(12):3739-45
references.pmid: 15315971
references.citation: Leukemia. 2002 Nov;16(11):2190-6
references.pmid: 12399961
references.citation: Blood. 2002 May 15;99(10):3547-53
references.pmid: 11986206
references.citation: Blood. 1985 Dec;66(6):1326-35
references.pmid: 3864497
references.citation: Blood. 2007 Dec 1;110(12):4005-11
references.pmid: 17785585
references.citation: J Pharmacol Exp Ther. 2000 Oct;295(1):139-45
references.pmid: 10991971
references.citation: Cancer Genet Cytogenet. 1985 Sep;18(1):65-79
references.pmid: 3861236
references.citation: Blood. 2008 Feb 1;111(3):1039-43
references.pmid: 17932248
references.citation: Blood. 2002 Mar 1;99(5):1527-35
references.pmid: 11861264
references.citation: J Clin Oncol. 2007 Oct 1;25(28):4445-51
references.pmid: 17906206
references.citation: N Engl J Med. 1999 Apr 29;340(17):1330-40
references.pmid: 10219069
references.citation: Blood. 2002 Sep 15;100(6):1965-71
references.pmid: 12200353
references.citation: Blood. 2006 Aug 15;108(4):1328-33
references.pmid: 16614241
references.citation: J Clin Oncol. 2010 May 10;28(14):2381-8
references.pmid: 20385986
references.citation: Blood. 2006 Sep 15;108(6):1809-20
references.pmid: 16709930